New breast lump or change

A multicenter retrospective cohort study evaluated 431 female childhood cancer survivors with subsequent breast cancer matched one-to-one with first primary breast cancer patients (N = 344 pairs). Survivors demonstrated nearly 3.5-fold greater mortality risk (HR 3.5, 95% CI = 2.17-5.57) despite comparable rates of guideline-concordant treatment (94% vs 93%). Treatment modifications included higher mastectomy rates (81% vs 60%) and reduced use of radiotherapy (18% vs 61%) and anthracyclines (47% vs 66%) due to prior childhood cancer treatment exposures. These constrained treatment options and excess mortality emphasize the urgency of prompt evaluation of any suspicious breast changes in childhood cancer survivors.

View Source →

Four models of breast cancer in Black female persons identified three efficient DBT screening strategies with median breast cancer mortality reductions of 31.2% to 39.6%, 219.4 to 309.0 life-years gained, and 11.7 to 15.5 deaths averted per 1,000 women. Despite equal screening, mortality disparities persisted at 42% higher rates for Black women. More intensive screening for Black women (biennial ages 40 or 45 to 79 versus ages 50-74 for the general population) could reduce the elevated disparity from 42% to 30%. Women with denser breast tissue or other risk factors such as first-degree family history also showed improved benefit-to-harm trade-offs with screening.

View Source →

The umbrella review of 19 systematic reviews covering 199 primary studies with circa 2,460,600 participants found that self-examination programs across four cancer types, including breast cancer (8 systematic reviews), aimed to detect abnormalities early. AMSTAR-2 assessment identified 4 high-quality and 2 moderate-quality reviews. Educational interventions and personalized risk information showed promise in increasing self-examination activity and awareness, supporting the importance of recognizing and acting on detected changes.

View Source →

In a cohort of 118,952 breast cancer patients, 517 (0.44%) developed multiple primary cancers, of whom 112 had synchronous malignancies. Among these synchronous cases, 63.4% were contralateral breast cancers, with 90.1% diagnosed at the same time or within one month of the first breast cancer diagnosis. Patients with synchronous contralateral breast cancer had significantly better outcomes than those with synchronous non-breast cancers: 5-year overall survival was 90.9% vs 66.3%, and 5-year disease-free survival was 62.5% vs 51.3%. The mean time to synchronous breast cancer detection was 0.4 months compared to 1 month for non-breast cancers (p = 0.0123).

View Source →

The Hong Kong Cancer Expert Working Group reviewed local and international evidence and recommended that all women seek timely medical attention for suspicious breast symptoms. Breast cancer is the most common cancer among women in Hong Kong, posing a significant healthcare burden. The CEWG determined that while population-based mammography screening evidence was unclear for average-risk asymptomatic women, prompt evaluation of suspicious symptoms remains critical for early detection. Women at high risk, including confirmed BRCA1/2 mutation carriers and those with family history, should pursue annual mammography screening, while moderate-risk women should consider screening every 2 to 3 years after informed discussion with their doctors.

View Source →

The BCTEG consensus panel reviewed data on contralateral breast cancer risk in patients with estrogen receptor-positive early breast cancer who completed 5 years of adjuvant endocrine therapy. Extended adjuvant therapy trials including MA.17 (n=5,187), MA.17R (n=1,918), and NSABP B-42 (n=3,966) demonstrated that the risk of recurrence persists beyond 5 years. The annual hazard of recurrence remains at approximately 1-2% per year for years 5-15 after diagnosis, supporting continued self-monitoring for contralateral breast changes.

View Source →

In a case-control study involving 122 breast cancer patients (61 cases vs. 61 controls), lower knowledge about breast cancer was associated with 1.86 times higher odds of delay in seeking treatment (OR=1.86, 95% CI 0.68-5.089). The study concluded that intensive counseling on breast cancer awareness drives women toward early detection, underscoring the importance of acting promptly on warning signs rather than delaying evaluation.

View Source →

The EUSOBI consensus position, endorsed by 30 national breast radiology bodies, emphasizes that mammography screening reduces breast cancer mortality by 40% in women aged 50-69 who participate. The position paper highlights that dedicated pathways exist for high-risk women, including breast MRI according to national or international guidelines. The consensus underscores that digital mammography improves sensitivity particularly in dense breasts, where cancers may be harder to detect clinically. Women with known risk factors should be aware that specialized screening pathways are recommended, reinforcing that any suspicious breast changes between screening intervals warrant prompt evaluation.

View Source →

This quasi-experimental study of 40 women aged 30-50 in Joho village, Mojolaban demonstrated that structured health education about breast self-examination significantly improved participants' ability to recognize breast cancer warning signs. The treatment group (n=20) achieved posttest knowledge scores of 17.10 compared to 14.25 in the control group (n=20), with the difference statistically significant at p=0.001. The study emphasizes BSE as an efficient and effective early detection method alongside mammography, enabling identification of breast cancer signs at earlier disease stages (down-staging), which is critical since breast cancer is the leading cause of cancer death among women.

View Source →

In a Dutch nationwide cohort of 2,548 women with clinically T1-2N0 triple-negative breast cancer diagnosed between 2005 and 2008, regional recurrence occurred in 2.9% of patients over 5 years of follow-up. Local recurrence was observed in 4.2%. Initial pathologic nodal involvement was found in 20.4% of patients (pN1mi 4.5%, pN1 12.3%, pN2-3 3.6%). Five-year disease-free survival was 78.7% and overall survival was 82.3%.

View Source →

The screening programme in Khanpur Kalan villages identified breast-related complaints among surveyed women including adenocarcinoma, axillary lumps, fibroadenosis, and fibrocystic disease. These conditions were detected in women who were otherwise considered normal or asymptomatic, highlighting that clinically significant breast disease can be present without obvious symptoms. The findings underscore that women who notice any new lump during self-examination should seek medical evaluation promptly, as the screening identified malignant pathology among participants who had not previously sought care.

View Source →

Among 173,797 breast cancer patients, tumour stage at detection strongly predicted survival. Five-year relative survival was 100% for tumours ≤1 cm in the 2006-2012 cohort (n=93,569). Mortality increased with progressing tumour size (T1c vs T1a: HR 1.54, 95% CI 1.33-1.78) and with increasing positive lymph nodes (N1 vs N0: HR 1.25, 95% CI 1.17-1.32). In the 2006-2012 cohort, 65% of patients (n=60,570) presented with tumours ≤T1 compared to 60% (n=48,031) in 1999-2005 (P<0.001), and these earlier-stage diagnoses contributed to improved overall survival of 96% at five years.

View Source →

In the Canadian National Breast Screening Study, 89,835 women were randomized to mammography or control arms. Physical breast examination alone detected cancers with equivalent mortality outcomes over 25 years of follow-up (HR 0.99, 95% CI 0.88-1.12 for cumulative breast cancer mortality). Of 3,250 breast cancers diagnosed in the mammography arm and 3,133 in controls, mortality was virtually identical (500 vs 505 deaths), confirming that physically detectable breast changes are important clinical indicators warranting evaluation, particularly when adjuvant therapy is freely available.

View Source →

Case-control study with 48 participants (24 per group) demonstrated that early breast examination practice is significantly related to perceived threat (p = 0.013) and perceived barriers (p = 0.021). The study context highlights that in Indonesia, 68.6% of breast cancer patients present at advanced stages with only 22.4% detected early. This disparity underscores the critical importance of acting on any abnormal findings discovered during self-examination, as delayed presentation is associated with worse disease staging at diagnosis.

View Source →

A matched paired case-control study with 38 breast cancer cases and 38 matched controls at Sanglah Hospital found breast disease history to be a highly significant risk factor on bivariate analysis (OR=13.5; 95%CI: 3.21-56.77, McNemar test). On multivariate logistic regression, breast infection history was the only independently significant risk factor with a dramatically elevated odds ratio (OR=43.19; 95%CI: 8.79-212.27). This indicates women with a history of breast disease or infection have over 43 times the odds of developing breast cancer compared to those without such history, underscoring the critical importance of early detection and prompt evaluation of any breast abnormalities.

View Source →

Among 28 Hodgkin's lymphoma survivors who developed breast cancer, a palpable lump was the mode of detection in 8 patients (28.6%). The median interval between Hodgkin's lymphoma treatment and breast cancer diagnosis was 16.1 years. Bilateral breast cancer occurred in 11 women (39.2%). Histological features and prognosis were similar to primary breast cancer in the 21-patient case-control analysis, but treatment differed significantly: mastectomy was predominant (P = .001), and adjuvant radiotherapy and anthracycline-based chemotherapy were used less frequently (P < .001 and P = .003, respectively).

View Source →

A non-randomized interventional study of 79 nurses at a tertiary hospital highlighted that breast cancer in developing countries is characterized by late presentation and significant morbidity and mortality. Initial knowledge scores on breast cancer awareness were only 18 out of 25 (72%), improving to 22 out of 25 (88%, p<0.001) after training. Practice skills for clinical breast examination started at 12.5 out of 30 (41.6%) and improved to 26 out of 30 (86.6%, p=0.003). The study underscores that increasing breast awareness is essential for early detection, as late presentation remains a major contributor to poor outcomes in breast cancer.

View Source →

The systematic review established that women with prior breast cancer have an increased risk of developing a second primary breast cancer for at least 20 years compared to the general population. Population studies using cancer registry data confirmed this sustained elevated risk. Self-detected recurrences demonstrated better survival than those found during routine clinical examination, indicating that prompt attention to self-noticed changes and fast access to medical treatment at point of need may improve outcomes. The review concluded that immediate access to specialist evaluation when women notice changes is preferable to relying solely on scheduled surveillance visits.

View Source →

A cohort of 1,541 women treated with radiotherapy (RT) and 4,570 not treated with RT for breast cancer, registered in the Swiss Vaud Cancer Registry (1978–1998) and followed to December 2002, showed elevated contralateral breast cancer rates in both groups. RT women had a standardised incidence ratio (SIR) of 1.85 (95% CI: 1.45–2.33) for contralateral breast cancer, while NRT women had an SIR of 1.38 (95% CI: 1.16–1.61). Overall, 20% of RT cases vs 16% of NRT cases developed a second neoplasm within 15 years. Total second neoplasms occurred at SIR 1.54 (95% CI: 1.32–1.78) in RT and SIR 1.13 (95% CI: 1.02–1.25) in NRT women.

View Source →

In the Edinburgh trial, interval cancer cases among screened women increased from 12% of control group incidence in the first year after screening to 67% by the third year. This was observed in 22,944 women monitored over a 3-year period prior to their first screen under the UK service screening programme, demonstrating that a substantial proportion of cancers arise between scheduled screening visits and underscoring the need for patients to seek evaluation for new breast symptoms promptly rather than waiting for the next screening appointment.

View Source →